This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Hated Stocks Set to Soar on Earnings

Regeneron Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

A potential earnings short-squeeze play in the biotechnology and drugs complex is Regeneron Pharmaceuticals (REGN - Get Report), which is set to release its numbers on Wednesday before the market open. This is an integrated biopharmaceutical firm, which discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Wall Street analysts, on average, expect Regeneron Pharmaceuticals to report revenue of $255.98 million on earnings of 25 cents per share.

If you're looking for a strong uptrending heavily-shorted biotech player ahead of its earnings report, then make sure to check out shares of Regeneron Pharmaceuticals. This stock has been on fire so far in 2012, with shares up over 121% so far. The current short interest as a percentage of the float for Regeneron Pharmaceuticals is notable at 6.3%. That means that out of the 88.13 million shares in the tradable float, 4.63 million shares are sold short by the bears.

>>5 Biotech Stocks Under $10 Set to Soar

From a technical perspective, REGN is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock recently found some big buying interest at around $107.31 to $111.50 a share. Since those buyers stepped in during the last month, shares of REGN have started to trend higher toward its current price of $122.50 a share and it's also moved within range of triggering a near-term breakout trade.

If you're in the bull camp on REGN, then I would wait until after its report and look for long-biased trades if this stock manages to take out some near-term overhead resistance at $124.85 a share (or its daily high from Tuesday if it's higher) with heavy volume. Look for volume on that move that registers near or above its three-month average action of 963,006 shares. If we get that move, then REGN will have a great chance of re-testing and possibly taking out its next major overhead resistance levels at $135 to $137.82 a share post-earnings.

I would simply avoid REGN or look for short-biased trades if after earnings this stock fails to trigger that breakout, and then moves back below Monday's low of $118.01 a share with heavy volume. If we get that move, then REGN will be trending back below its 50-day moving average of $122.51 a share, and this stock will likely head back towards those near-term support levels at $111.50 to $107.31 a share. If REGN takes out $107.31 a share with volume post-earnings, then this stock could easily fall all the way back towards its 200-day moving average of $95.68 a share if the bears slam this stock post-earnings.

Regeneron shows up on a recent list of 10 Stocks of Top-Performing Mutual Funds in 2012.
3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DDD $13.64 -6.00%
REGN $378.39 4.90%
TRIP $62.05 -1.70%
SYNC $3.37 140.00%
WRLD $39.35 -10.00%


Chart of I:DJI
DOW 17,626.85 -24.41 -0.14%
S&P 500 2,051.41 +0.29 0.01%
NASDAQ 4,725.6260 -0.0130 -0.00%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs